Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.86 |
| ▸ | CHAT | P28329 | 2/20 | 0.82 |
| ▸ | EP300 | Q09472 | 3/20 | 0.81 |
| ▸ | AURKA | O14965 | 2/20 | 0.81 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.81 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.81 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22612561 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL26135395 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL1533824 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL30411982 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL22609304 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL29699328 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL2935253 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL22612510 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL28487648 | 0.98 | NAA50 (0.84) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL30046331 | 0.96 | NAA50 (0.84) | NAA50CHATEP300AURKAKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 382 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250207166-A1 | BIOSYNTHESIS | PLANT BIOSCIENCE LTD (GB) | 2025-06-26 | — | — | US | claimed |
| EP-4499817-A1 | BIOSYNTHESIS | Plant Bioscience Limited (GB) | 2025-02-05 | — | — | EP | claimed |
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | HEMOSHEAR THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | claimed |
| EP-4319746-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Hemoshear Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | claimed |
| US-20230383319-A1 | ITERATIVE PLATFORM FOR THE SYNTHESIS OF ALPHA FUNCTIONALIZED PRODUCTS | Gonzalez, Ramon (US) | 2023-11-30 | — | — | US | claimed |
| WO-2023180677-A1 | Biosynthesis | PLANT BIOSCIENCE LIMITED (GB) | 2023-09-28 | — | — | WO | claimed |
| CN-110087647-B | Amino acid composition and method for treating liver disease | 胺细拉健康公司 | 2023-06-16 | — | — | CN | claimed |
| CN-115725665-A | Hyperforin biosynthesis gene cluster and application thereof | 中国科学院分子植物科学卓越创新中心 | 2023-03-03 | — | — | CN | claimed |
| WO-2022216848-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Hemoshear Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| US-9421262-B2 | Compositions and methods for treating dermatological conditions | BIOMED RESEARCH & TECHNOLOGIES, INC. (US) | 2016-08-23 | — | — | US | claimed |
| WO-2011051813-A1 | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS | PAUL HARBHAJAN S (US) | 2011-05-05 | — | — | WO | claimed |
| US-20110098229-A1 | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS | BIOMED RESEARCH & TECHNOLOGIES, INC. | 2011-04-28 | — | — | US | claimed |
| CN-101356266-A | Novel gene products of Bacillus licheniformis producing odorous substances and improved biotechnological production methods based thereon | HENKEL KGAA (DE) | 2009-01-28 | — | — | CN | claimed |
| US-20070190605-A1 | GENE PRODUCTS OF BACILLUS LICHENIFORMIS WHICH FORM ODOROUS SUBSTANCES AND IMPROVED BIOTECHNOLOGICAL PRODUCTION METHODS BASED THEREON | BASF SE (DE) | 2007-08-16 | — | — | US | claimed |
| EP-1761628-A2 | NOVEL GENE PRODUCTS OF BACILLUS LICHENIFORMIS WHICH FORM ODOROUS SUBSTANCES AND IMPROVED BIOTECHNOLOGICAL PRODUCTION METHODS BASED THEREON | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-03-14 | — | — | EP | claimed |
| WO-2006000343-A2 | NOVEL GENE PRODUCTS OF BACILLUS LICHENIFORMIS WHICH FORM ODOROUS SUBSTANCES AND IMPROVED BIOTECHNOLOGICAL PRODUCTION METHODS BASED THEREON | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-01-05 | — | — | WO | claimed |
| EP-1098630-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | Biomed Research and Technologies, Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-6149924-A | FOR TOPICAL APPLICATION | BIOMED RESEARCH & TECHNOLOGIES, INC. (US) | 2000-11-21 | — | — | US | claimed |
| WO-2000004870-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | BIOMED RESEARCH AND TECHNOLOGIES, INC. (US) | 2000-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | MMAB, OTC, ME2 | NAA50 3556/4885CHAT 1146/4885EP300 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.